Maisonneuve-Rosemont Hospital Research Centre

A hotbed of research and innovation in cellular and molecular therapy and regenerative medicine, the Maisonneuve-Rosemont Hospital Research Centre (CR-HMR) conducts human clinical research in its three major fields of excellence: immunology-oncology, nephrology and vision health. Affiliated with the Université de Montréal, it is part of the CIUSSS de l’Est-de-l’Île-de-Montréal and serves a population of more than 535,000.

With over 200 physician-scientists and more than 30 experienced clinical research teams, the CR-HMR is a well-established research facility. It currently has 140 clinical trials under way, 14 of which are phase l and/or ll trials. These early-stage trials are mainly in hematology-oncology, nephrology, ophthalmology and radiation oncology.

The ability of our physician-scientists to initiate and participate in clinical studies is facilitated by close collaboration with the cutting-edge clinical services in the medical specialties of the major areas of excellence. This ability is also propelled by the institution’s Centre of Excellence in Cellular Therapy (CETC), a GMP-certified centre that is one of the most highly developed and sophisticated in the world and a leading asset for Quebec, as well as by the Centre for Commercialization of Cancer Immunotherapy (C3i), a biotech organization active in the field of cellular therapy.

Services

• Access to all clinical areas, including critical care, as well as to beds for conducting clinical trials;
• Investigational drug management by a dedicated section of the Maisonneuve-Rosemont Hospital pharmacy;
• Medical imaging with the Maisonneuve-Rosemont Hospital’s services and possibility of special interpretation;
• Possibility of drawing up a master service agreement with the institution;
• Informed consent templates preapproved by the ethics review board and ready for customization;
• Legal evaluation department accustomed to dealing with industry-sponsored research projects;
• Competitive authorization times for research projects;
• CETC technical platform: production of viral vectors used in clinical trials;
• Centre for Commercialization of Cancer Immunotherapy – C3i.